Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Esperion Therapeutics, Inc. - Common Stock (NQ:ESPR)

3.115 +1.115 (+55.75%)
Streaming Delayed Price Updated: 3:25 PM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 171,334,398
Open 3.130
Bid (Size) 3.110 (706,200)
Ask (Size) 3.120 (653,400)
Prev. Close 2.000
Today's Range 3.100 - 3.140
52wk Range 0.6925 - 4.175
Shares Outstanding 28,277,493
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's going on in today's session ↗
Via Chartmill
News headline image
Veeva Systems, Five9, AXT And Other Big Stocks Moving Higher On Friday ↗
US stocks were mixed on Friday, with Dow Jones down 0.1%. Veeva Systems Inc (NYSE: VEEV) rose 11.6%, joining S&P 500 on May 7. Other big gainers: Esperion Therapeutics Inc (NASDAQ: ESPR), Five9 Inc... 
Via Benzinga
Topics Artificial Intelligence Stocks

Performance

YTD
-16.0%
-16.0%
1 Month
+13.7%
+13.7%
3 Month
-12.3%
-12.3%
6 Month
+9.7%
+9.7%
1 Year
+211.7%
+211.7%

More News

Read More
Friday's session: most active stocks ↗
Via Chartmill
Which stocks are moving on Friday? ↗
Via Chartmill
Esperion Therapeutics Inc (NASDAQ:ESPR) Reports Mixed Q4 2025 Results Amid Strategic Expansion ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
ESPR Stock Alert: Halper Sadeh LLC is Investigating Whether Esperion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Esperion to be Acquired by ARCHIMED
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Report First Quarter 2026 Financial Results on May 7
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics
From Athyrium Capital Management, LP
Via GlobeNewswire
News headline image
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts ↗
Via Stocktwits
Topics Intellectual Property
News headline image
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
From Corstasis Therapeutics Inc.
Via Business Wire
News headline image
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in The 2026 Citizens Life Sciences Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Esperion Therapeutics, Inc. - Common Stock publicly traded?
Yes, Esperion Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Esperion Therapeutics, Inc. - Common Stock trade on?
Esperion Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Esperion Therapeutics, Inc. - Common Stock?
The ticker symbol for Esperion Therapeutics, Inc. - Common Stock is ESPR on the Nasdaq Stock Market
What is the current price of Esperion Therapeutics, Inc. - Common Stock?
The current price of Esperion Therapeutics, Inc. - Common Stock is 3.115
When was Esperion Therapeutics, Inc. - Common Stock last traded?
The last trade of Esperion Therapeutics, Inc. - Common Stock was at 05/01/26 03:25 PM ET
What is the market capitalization of Esperion Therapeutics, Inc. - Common Stock?
The market capitalization of Esperion Therapeutics, Inc. - Common Stock is 88.08M
How many shares of Esperion Therapeutics, Inc. - Common Stock are outstanding?
Esperion Therapeutics, Inc. - Common Stock has 88M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.